STOCKHOLM: US Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group’s top executive was quoted as saying by Swedish business daily Dagens Industri.
AstraZeneca saw off a US$118bil approach from Pfizer in May and British takeover rules now allow Pfizer to renew its pursuit.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!